6533b870fe1ef96bd12d0683
RESEARCH PRODUCT
The calm before the storm: a report from the International Liver Cancer Association Congress 2015 – part 1
Maria ReigRodolfo SaccoGennaro Gadaleta-caldarolaJean-charles NaultJean-charles NaultCarlo SaittaGiovanni GalatiGiuseppe LombardiGiuseppe CabibboGian Carlo MazzaLuca Marzisubject
SorafenibCancer Researchmedicine.medical_specialtysurvivalliver cancer03 medical and health sciences0302 clinical medicineInternal medicinestaging systemmedicineHumansHCCDisease management (health)Staging systembusiness.industryCarcinomaLiver NeoplasmsDisease ManagementHCC; immunotherapy; liver cancer; prognosis; sorafenib; staging system; survival; trial design; Carcinoma Hepatocellular; Disease Management; Humans; Liver Neoplasms; Oncology; Cancer ResearchHepatocellularGeneral MedicineHepatologymedicine.diseaseOncology030220 oncology & carcinogenesisFamily medicinetrial designsorafenib030211 gastroenterology & hepatologyimmunotherapyprognosisLiver cancerbusinessmedicine.drugdescription
International Liver Cancer Association Congress 2015, Paris, France, 4–6 September 2015 Since its creation 9 years ago, in 2007, the International Liver Cancer Association has focused on the multidisciplinary approach to liver cancer due to advances in hepatology science and care worldwide. In its 2015 annual conference, held on 4–6 September in Paris, France, the most recent progresses in the basic biology, management and treatment of liver cancer have been presented. This report, divided into two parts, introduces and critically reviews some of the most intriguing topics discussed at the meeting.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2016-02-01 | Future Oncology |